Skip to main content
OpenTrials
Completed

NCT Number: NCT02855541

Health Effects of Increasing Muscle Activation While Sitting in Office Workers

Previous research suggests that prolonged sitting increases risk for cardiometabolic diseases and the risk factors associated with cardiometabolic diseases. However, no study to date has examined if a chronic intervention that breaks up prolonged sitting in a real-world environment results in a reduction in the metabolic risk factors associated with cardiometabolic diseases. Thus, the objective of this study is to examine the potential health benefits of breaking up sitting bouts throughout the workday using a small cycling device (DeskCycle) in office workers involved with jobs that require prolonged bouts of sitting. The investigators hypothesize that breaking up sitting will be associated with improvements in cardiometabolic disease risk factors. More specifically, the investigators hypothesize that breaking up sitting will decrease blood glucose during an oral glucose tolerance test (OGTT), increase cardiorespiratory fitness (VO2max), decrease blood pressure, decrease body fat, increase HDL cholesterol, and decrease LDL cholesterol, total cholesterol, and triglycerides.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Colorado Boulder

Boulder, Colorado, 80309, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Both males and females
  • Subjects will need to be 18-55 years old
  • Subjects will need to be sitting at least 6 hours/day on 5 days/week
  • Subjects will need to be exercising less than 5 hour/week

Exclusion criteria

  • Females that are pregnant or breast-feeding.
  • Subjects must be free from any acute or chronic physical condition that would influence the outcome measures of the protocol. Examples include, but are not limited to advanced chronic disease states (chronic kidney, liver, heart, or lung disease), morbid obesity, emphysema, and an inability to use the legs for normal locomotion. Normality will be established on the basis of clinical history, physical exam, and vital signs. Any subject with a history of an uncontrolled metabolic disorder/disease or symptoms of active illness will be excluded from study. Any subject with a history of an uncontrolled metabolic disorder/disease such as diabetes (Type I or Type II) or symptoms of active illness will be excluded from study.
  • Subjects will be excluded if they have a fasted blood glucose level >126 mg/dl or a systolic blood pressure >140 mmHg.
  • Medical/psychiatric/sleep disorders history: any clinically significant unstable medical or psychological condition within the last year (treated or untreated).
  • Drug use:
  • Use of any medications, including over-the-counter and herbal products, that may affect metabolic function within 1 month prior to the study or need to use any of these medications at any time during the study (self-report by interview). Examples of potential medications that will exclude a subject include: beta-adrenergic blockers, sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, and dipeptidyl peptidase IV inhibitors. Note, subjects may be tested at a later date.
  • Use of any investigational drug within 1 month before the study

Treatment and study plan

DeskCycle

Device

A small cycling ergometer that can fit under a desk at the workplace.

Primary outcomes

  1. Blood Glucose

    Time frame: Measured after 4 weeks

    2-h Post Oral Glucose Tolerance Test Blood Glucose

  2. Maximum Oxygen Consumption

    Time frame: Measured after 4 weeks

    Maximum oxygen consumption (VO2max) will be used to determine physical fitness

Secondary outcomes

  1. Systolic Blood Pressure

    Time frame: Measured after 4 weeks

  2. HDL Cholesterol

    Time frame: Measured after 4 weeks

  3. LDL Cholesterol

    Time frame: Measured after 4 weeks

  4. Triglycerides

    Time frame: Measured after 4 weeks

  5. Lean Mass

    Time frame: Measured after 4 weeks

  6. Fat Mass

    Time frame: Measured after 4 weeks

Sponsors and collaborators

Lead sponsor

University of Colorado, Boulder

Other

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Aug 4, 2016
Registry last updated
Nov 13, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.